SERA PROGNOSTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS
Sera Prognostics (NASDAQ: SERA) reported its Q2 2025 financial results, showing revenue of $17,000, down from $24,000 in Q2 2024. The company recorded a net loss of $8.0 million, slightly improved from $8.3 million in the prior year.
Operating expenses remained flat at $9.3 million, with R&D expenses decreasing 24% to $3.3 million while SG&A expenses increased to $6.0 million. The company maintains a strong financial position with $108.5 million in cash and securities, expected to fund operations through 2028.
Sera strengthened its leadership team with key appointments, including Lee Anderson as Chief Commercial Officer, Chuck Hyde as Head of Market Access, and Jennifer Zibuda as Head of Investor Relations. The company is progressing with Medicaid plan engagement and preparing to publish full results of its PRIME study.
Sera Prognostics (NASDAQ: SERA) ha comunicato i risultati finanziari del secondo trimestre 2025, con un fatturato di 17.000 dollari, in calo rispetto ai 24.000 dollari del secondo trimestre 2024. L'azienda ha registrato una perdita netta di 8,0 milioni di dollari, leggermente migliorata rispetto agli 8,3 milioni dell'anno precedente.
Le spese operative sono rimaste stabili a 9,3 milioni di dollari, con una riduzione del 24% delle spese di R&S a 3,3 milioni di dollari, mentre le spese SG&A sono aumentate a 6,0 milioni di dollari. L'azienda mantiene una solida posizione finanziaria con 108,5 milioni di dollari in contanti e titoli, sufficienti a finanziare le operazioni fino al 2028.
Sera ha rafforzato il team dirigenziale con nomine chiave, tra cui Lee Anderson come Chief Commercial Officer, Chuck Hyde come responsabile Market Access e Jennifer Zibuda come responsabile delle relazioni con gli investitori. L'azienda sta avanzando nell'engagement con i piani Medicaid e si sta preparando a pubblicare i risultati completi dello studio PRIME.
Sera Prognostics (NASDAQ: SERA) report贸 sus resultados financieros del segundo trimestre de 2025, mostrando ingresos de $17,000, una disminuci贸n respecto a los $24,000 del segundo trimestre de 2024. La compa帽铆a registr贸 una p茅rdida neta de $8.0 millones, ligeramente mejor que los $8.3 millones del a帽o anterior.
Los gastos operativos se mantuvieron estables en $9.3 millones, con una reducci贸n del 24% en gastos de I+D a $3.3 millones, mientras que los gastos SG&A aumentaron a $6.0 millones. La empresa mantiene una s贸lida posici贸n financiera con $108.5 millones en efectivo y valores, lo que se espera financie las operaciones hasta 2028.
Sera fortaleci贸 su equipo directivo con nombramientos clave, incluyendo a Lee Anderson como Chief Commercial Officer, Chuck Hyde como Jefe de Acceso al Mercado y Jennifer Zibuda como Jefa de Relaciones con Inversionistas. La compa帽铆a avanza en la participaci贸n con planes Medicaid y se prepara para publicar los resultados completos de su estudio PRIME.
Sera Prognostics (NASDAQ: SERA)電� 2025雲� 2攵勱赴 鞛 鞁れ爜鞚� 氚滍憸頄堨溂氅�, 毵れ稖鞚� 17,000雼煬搿� 2024雲� 2攵勱赴鞚� 24,000雼煬鞐愳劀 臧愳唽頄堨姷雼堧嫟. 須岇偓電� 800毵� 雼煬鞚� 靾滌啇鞁�鞚� 旮半頄堨溂氅�, 鞚措姅 鞝勲厔霃勳潣 830毵� 雼煬鞐愳劀 雼れ唽 臧滌劆霅� 靾橃箻鞛呺媹雼�.
鞓侅梾牍勋毄鞚赌 930毵� 雼煬搿� 鞙犾霅橃棃鞙茧┌, 鞐瓣惮臧滊皽牍勲姅 24% 臧愳唽頃� 330毵� 雼煬, 韺愲Г甏�毽箘電� 600毵� 雼煬搿� 歃濌皜頄堨姷雼堧嫟. 須岇偓電� 1鞏� 850毵� 雼煬鞚� 順勱笀 氚� 鞙犼皜歃濌秾鞚� 氤挫湢頃橃棳 2028雲勱箤歆� 鞖挫榿 鞛愱笀鞚� 頇曤炒頃橁碃 鞛堨姷雼堧嫟.
Sera電� 欤检殧 鞛勳洂歆� 氤搓皶鞚� 韱淀暣 毽� 鞎る崝鞀�鞚� 斓滉碃 靸侅梾 毂呾瀯鞛�, 觳� 頃橃澊霌�毳� 鞁滌灔 鞝戧芳 毂呾瀯鞛�, 鞝滊媹韻� 歆�攵�雼�毳� 韴瀽鞛� 甏�瓿� 毂呾瀯鞛愲 鞛勲獏頄堨姷雼堧嫟. 須岇偓電� 氅旊敂旒�鞚措摐 瓿勴殟 彀胳棳毳� 歆勴枆 欷戩澊氅� PRIME 鞐瓣惮鞚� 鞝勳泊 瓴瓣臣 氚滍憸毳� 欷�牍勴晿瓿� 鞛堨姷雼堧嫟.
Sera Prognostics (NASDAQ : SERA) a publi茅 ses r茅sultats financiers du deuxi猫me trimestre 2025, affichant un chiffre d'affaires de 17 000 $, en baisse par rapport 脿 24 000 $ au deuxi猫me trimestre 2024. La soci茅t茅 a enregistr茅 une perte nette de 8,0 millions de dollars, l茅g猫rement am茅lior茅e par rapport 脿 8,3 millions l'ann茅e pr茅c茅dente.
Les d茅penses d'exploitation sont rest茅es stables 脿 9,3 millions de dollars, avec une baisse de 24 % des d茅penses de R&D 脿 3,3 millions de dollars, tandis que les d茅penses SG&A ont augment茅 脿 6,0 millions de dollars. L'entreprise conserve une solide position financi猫re avec 108,5 millions de dollars en liquidit茅s et titres, ce qui devrait financer ses op茅rations jusqu'en 2028.
Sera a renforc茅 son 茅quipe de direction avec des nominations cl茅s, notamment Lee Anderson en tant que Chief Commercial Officer, Chuck Hyde en tant que responsable de l'acc猫s au march茅, et Jennifer Zibuda en tant que responsable des relations investisseurs. La soci茅t茅 progresse dans l'engagement aupr猫s des plans Medicaid et se pr茅pare 脿 publier les r茅sultats complets de son 茅tude PRIME.
Sera Prognostics (NASDAQ: SERA) ver枚ffentlichte seine Finanzergebnisse f眉r das zweite Quartal 2025 mit einem Umsatz von 17.000 US-Dollar, was einen R眉ckgang gegen眉ber 24.000 US-Dollar im zweiten Quartal 2024 darstellt. Das Unternehmen verzeichnete einen Nettoverlust von 8,0 Millionen US-Dollar, der sich leicht gegen眉ber 8,3 Millionen US-Dollar im Vorjahr verbesserte.
Die Betriebskosten blieben mit 9,3 Millionen US-Dollar stabil, wobei die F&E-Ausgaben um 24 % auf 3,3 Millionen US-Dollar sanken, w盲hrend die SG&A-Ausgaben auf 6,0 Millionen US-Dollar anstiegen. Das Unternehmen verf眉gt 眉ber eine starke Finanzlage mit 108,5 Millionen US-Dollar in bar und Wertpapieren, die voraussichtlich den Betrieb bis 2028 finanzieren werden.
Sera hat sein F眉hrungsteam mit wichtigen Ernennungen verst盲rkt, darunter Lee Anderson als Chief Commercial Officer, Chuck Hyde als Leiter Market Access und Jennifer Zibuda als Leiterin Investor Relations. Das Unternehmen macht Fortschritte bei der Einbindung von Medicaid-Pl盲nen und bereitet die Ver枚ffentlichung der vollst盲ndigen Ergebnisse seiner PRIME-Studie vor.
- Strong cash position of $108.5 million, sufficient to fund operations through 2028
- Net loss improved to $8.0 million from $8.3 million year-over-year
- R&D expenses decreased by 24% following PRIME study completion
- Notable traction in Medicaid plans in states with high premature birth rates
- Revenue declined to $17,000 from $24,000 year-over-year
- SG&A expenses increased to $6.0 million from $4.9 million year-over-year
Insights
Sera's Q2 shows minimal revenue, declining R&D costs, increased SG&A spending, and substantial $108.5M cash runway through 2028.
Sera Prognostics' Q2 2025 financial performance reveals a company still in early commercialization with
The flat total operating expenses of
Net loss improved slightly to
The company's focus on Medicaid plans in states with high premature birth rates represents a targeted go-to-market strategy for their PreTRM test. This approach makes strategic sense given that Medicaid covers approximately
Sera's Q2 shows strategic commercial repositioning with key leadership hires, pending PRIME study publication, and targeted Medicaid approach.
Sera Prognostics is executing a methodical commercialization strategy for its PreTRM test that prioritizes payer engagement over immediate revenue generation. The company's strategic focus on Medicaid plans in states with above-average premature birth rates is particularly noteworthy, as these represent both significant medical need and substantial potential revenue streams.
The appointment of Lee Anderson as Chief Commercial Officer, Chuck Hyde as Head of Market Access, and Jennifer Zibuda as Head of Investor Relations signals a deliberate strengthening of the company's commercial infrastructure. Particularly significant is Hyde's background in market access for oncology diagnostics, as diagnostic reimbursement expertise will be crucial for navigating the complex Medicaid landscape across different states.
The pending publication of the full PRIME study results represents a critical inflection point for Sera's commercial trajectory. Diagnostic companies typically see accelerated adoption following the publication of definitive clinical data, especially when accompanied by health economic analyses that demonstrate cost savings to payers. The company's planned release of Medicaid-specific cost-saving analyses shows sophisticated understanding of payer decision-making processes.
The
Second Quarter and Recent Highlights:
- Ongoing progress in engaging Medicaid plans in targeted states with prior PreTRM clinical study experience. Notable traction in two particular states with above-average premature birth rates, presenting strong commercial opportunities, alongside growing momentum in two additional states with leading healthcare systems and significant physician interest.
- On track to publish the full study results of Sera's Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs ("PRIME") this year, followed swiftly by additional data on health economic benefits, sub-population analysis and Medicaid expected cost-saving benefits of Sera's PreTRM Test.
- Strengthened Sera's leadership team with several recent appointments:
- In May, Sera announced the appointment of Lee Anderson as Chief Commercial Officer. Bringing more than 30 years of cross-functional leadership experience in sales, marketing, customer service, strategic accounts, and training, Mr. Anderson has a proven track record of driving business growth and enhancing sales strategies in the healthcare sector.
- In July, Sera appointed two additional leaders to the team.
- Chuck听Hyde was appointed as the Company's Head of Market Access. Mr. Hyde brings over 20 years of expertise in market access, including leadership roles in oncology diagnostics and pharmaceuticals, to further strengthen Sera's commercial capabilities. Notably, he previously held an instrumental role guiding the payer team at a groundbreaking cancer diagnostic company.
- Jennifer听Zibuda was appointed as Sera's Head of Investor Relations. Ms. Zibuda is an experienced investor relations veteran with buy-side, sell-side and healthcare experience to further broaden Sera's exposure within the investment community as the Company expands commercialization toward anticipated revenue growth.
"We continue to build the foundation needed for the expected acceleration in commercial momentum now that our full PRIME pivotal study results are in hand, which is enabling engaged conversations and increased traction with managed Medicaid and other organizations," said Zhenya Lindgardt, President and CEO of Sera Prognostics. "Furthermore, we plan to share additional compelling data and evidence showing that our PreTRM test can truly make a difference in addressing the impact of premature births while empowering doctors with actionable information to improve pregnancy outcomes and reduce healthcare costs."
Second Quarter 2025 Financial Results
Second quarter 2025 revenue was
Total operating expenses were
Research and development expenses for the second quarter of 2025 were
Selling, general and administrative expenses for the second quarter of 2025 were
Net loss for the quarter was
As of June 30, 2025, the Company had cash, cash equivalents, and available-for-sale securities of approximately
Conference Call Information
Sera Prognostics will host a corresponding conference call and live webcast today to discuss second quarter 2025 operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing the following:
US domestic callers: (800) 836-8184
International callers: (646) 357-8785
Webcast Registration Link:
Live audio of the webcast will be available online from the Investors page of the Company's website at听. The webcast will be archived on the Investors page and will be available for one year.
About Sera Prognostics, Inc.
Sera Prognostics is a leading health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera's mission is to provide early, pivotal pregnancy information to improve the health of mothers and newborns, resulting in reductions in the costs of healthcare delivery. Sera has a robust pipeline of innovative diagnostic tests focused on the early prediction of preterm birth risk and other complications of pregnancy. Sera's precision medicine PreTRM庐 Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk. Sera Prognostics is headquartered in
About Preterm Birth
Preterm birth is defined as any birth before 37 weeks' gestation and is the leading cause of illness and death in newborns. The 2024 March of Dimes Report Card shows that, for the last six consecutive years, more than one in ten infants is born prematurely in
About the PreTRM庐 Test
The PreTRM庐 Test is the only broadly validated, commercially available blood-based biomarker test that provides an early, accurate and individualized risk prediction for spontaneous preterm birth in asymptomatic singleton pregnancies. The PreTRM庐 Test measures and analyzes proteins in the blood that are highly predictive of preterm birth. The PreTRM庐 Test permits physicians to identify, during the weeks 18 through 20 of pregnancy, which women are at increased risk for preterm birth and its complications, enabling more informed, personalized clinical decisions based on each woman's individual risk. The PreTRM庐 Test is ordered by a medical professional.
Sera, Sera Prognostics, the Sera Prognostics logo, The Pregnancy Company, and PreTRM are trademarks or registered trademarks of Sera Prognostics, Inc. in听the United States听and/or other countries.
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to ongoing progress in engaging Medicaid plans in targeted states; publishing full study results of the PRIME study this year, followed swiftly by additional data on health economic benefits, sub-population analysis and Medicaid expected cost-saving benefits of the PreTRM Test; further broadening the Company's exposure within the investment community as it expands commercialization toward anticipated revenue growth; expected acceleration in commercial momentum; increased traction with managed Medicaid and other organizations; sharing additional compelling data and evidence showing the PreTRM test can address premature births, empower doctors with actionable information; and reduce healthcare costs; the Company's cash, cash equivalents, and available-for-sale securities of approximately
Contact
Investor Contact
Jennifer Zibuda, Head of Investor Relations
[email protected]
+1 (801) 396-8043
听
SERA PROGNOSTICS, INC. | ||||||||
Condensed Statements of Operations | ||||||||
(unaudited) | ||||||||
(in thousands, except share and per share data) | ||||||||
Three Months Ended | Six Months Ended | |||||||
June 30,听 | June 30,听 | |||||||
2025 | 2024 | 2025 | 2024 | |||||
Revenue | $听听听听听听听听听听听听听听听听听听听听听听听听 17 | $听听听听听听听听听听听听听听听听听听听听听听听听 24 | $听听听听听听听听听听听听听听听听听听听听听听听听 55 | $听听听听听听听听听听听听听听听听听听听听听听听听 24 | ||||
Operating expenses: | ||||||||
Cost of revenue | 41 | 20 | 81 | 37 | ||||
Research and development | 3,337 | 4,406 | 6,671 | 8,089 | ||||
Selling and marketing | 1,821 | 1,099 | 3,291 | 2,326 | ||||
General and administrative | 4,138 | 3,752 | 8,582 | 7,922 | ||||
Total operating expenses | 9,337 | 9,277 | 18,625 | 18,374 | ||||
Loss from operations | (9,320) | (9,253) | (18,570) | (18,350) | ||||
Interest expense | (2) | (8) | (6) | (17) | ||||
Other income, net | 1,276 | 958 | 2,343 | 1,967 | ||||
Net loss | $听听听听听听听听听听听听听听听听听 (8,046) | $听听听听听听听听听听听听听听听听听 (8,303) | $听听听听听听听听听听听听听听听 (16,233) | $听听听听听听听听听听听听听听听 (16,400) | ||||
Net loss per share, basic and diluted | $听听听听听听听听听听听听听听听听听听听 (0.16) | $听听听听听听听听听听听听听听听听听听听 (0.25) | $听听听听听听听听听听听听听听听听听听听 (0.36) | $听听听听听听听听听听听听听听听听听听听 (0.50) | ||||
Weighted-average shares outstanding, basic and diluted | 49,066,398 | 32,932,903 | 45,536,846 | 32,576,470 | ||||
听
SERA PROGNOSTICS, INC. | ||||
Condensed Balance听Sheets | ||||
(unaudited) | ||||
(in thousands) | ||||
June 30,听 | December听31, | |||
2025 | 2024 | |||
Assets | ||||
Current assets: | ||||
Cash and cash equivalents | $听听听听听听听听听听听听听听听听听听听 5,016 | $听听听听听听听听听听听听听听听听听听听 4,043 | ||
Marketable securities | 35,144 | 42,193 | ||
Accounts receivable | 17 | 34 | ||
Prepaid expenses and other current assets | 693 | 1,330 | ||
Total current assets | 40,870 | 47,600 | ||
Property and equipment, net | 1,204 | 1,239 | ||
Long-term marketable securities | 68,351 | 21,973 | ||
Intangible assets, net | 968 | 1,026 | ||
Other assets | 435 | 737 | ||
Total assets | $听听听听听听听听听听听听听听听 111,828 | $听听听听听听听听听听听听听听听听听 72,575 | ||
Liabilities and Stockholders' Equity | ||||
Current liabilities:听 | ||||
Accounts payable | $听听听听听听听听听听听听听听听听听听听 1,063 | $听听听听听听听听听听听听听听听听听听听 1,969 | ||
Accrued and other current liabilities | 2,296 | 2,384 | ||
Finance lease obligation, current portion | 23 | 194 | ||
Deferred revenue | 20,220 | 20,223 | ||
Total current liabilities | 23,602 | 24,770 | ||
Finance lease obligation, net of current portion | 鈥� | 2 | ||
Total liabilities | 23,602 | 24,772 | ||
Commitments and contingencies | ||||
Stockholders' equity: | ||||
Common stock, Class A and Class B | 4 | 3 | ||
Additional paid-in capital | 384,104 | 327,534 | ||
Accumulated other comprehensive income | 145 | 60 | ||
Accumulated deficit | (296,027) | (279,794) | ||
Total stockholders' equity | 88,226 | 47,803 | ||
Total liabilities and stockholders' equity | $听听听听听听听听听听听听听听听 111,828 | $听听听听听听听听听听听听听听听听听 72,575 | ||
听
View original content to download multimedia:
SOURCE Sera Prognostics, Inc.
FAQ
What were Sera Prognostics (SERA) Q2 2025 earnings results?
How much cash does Sera Prognostics have and how long will it last?
Who are the new executives joining Sera Prognostics in 2025?
What is the status of Sera's PRIME study results?
How did Sera's operating expenses change in Q2 2025?
